PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Consensus Recommendation of “Hold” by Analysts

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has earned an average rating of “Hold” from the sixteen brokerages that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $25.0909.

Several research analysts recently commented on the stock. UBS Group lowered shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price target on the stock. in a report on Tuesday, July 28th. William Blair downgraded shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Leerink Partners lowered shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $31.00 to $29.00 in a research report on Thursday, June 11th. TD Cowen cut their target price on shares of PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Finally, Citigroup downgraded shares of PROCEPT BioRobotics to a “hold” rating in a research note on Thursday, July 2nd.

PROCEPT BioRobotics Price Performance

PRCT stock opened at $20.91 on Wednesday. The stock has a 50-day moving average price of $20.33 and a two-hundred day moving average price of $23.78. PROCEPT BioRobotics has a 12-month low of $16.67 and a 12-month high of $42.43. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.20 billion, a PE ratio of -10.78 and a beta of 0.91.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The firm had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The business’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.35) earnings per share. As a group, research analysts predict that PROCEPT BioRobotics will post -1.67 EPS for the current year.

Insider Transactions at PROCEPT BioRobotics

In related news, CEO Larry L. Wood acquired 23,900 shares of the business’s stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $20.85 per share, with a total value of $498,315.00. Following the completion of the transaction, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at $498,315. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders sold 1,000 shares of company stock valued at $28,480. 4.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On PROCEPT BioRobotics

Institutional investors and hedge funds have recently modified their holdings of the stock. VELA Investment Management LLC raised its holdings in shares of PROCEPT BioRobotics by 62.0% during the 2nd quarter. VELA Investment Management LLC now owns 113,722 shares of the company’s stock valued at $2,568,000 after buying an additional 43,513 shares during the period. Corient Private Wealth LP lifted its position in PROCEPT BioRobotics by 89.9% during the 2nd quarter. Corient Private Wealth LP now owns 108,455 shares of the company’s stock worth $2,449,000 after acquiring an additional 51,336 shares in the last quarter. Amundi boosted its holdings in PROCEPT BioRobotics by 329.8% in the 2nd quarter. Amundi now owns 100,539 shares of the company’s stock worth $2,270,000 after acquiring an additional 77,145 shares during the period. California State Teachers Retirement System boosted its holdings in PROCEPT BioRobotics by 2,104.3% in the 2nd quarter. California State Teachers Retirement System now owns 1,547,069 shares of the company’s stock worth $34,933,000 after acquiring an additional 1,476,885 shares during the period. Finally, FirstWave Capital Management LLC grew its position in PROCEPT BioRobotics by 79.7% in the second quarter. FirstWave Capital Management LLC now owns 144,408 shares of the company’s stock valued at $3,261,000 after acquiring an additional 64,069 shares in the last quarter. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Key Stories Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Analysts have an average “Hold” recommendation on PROCEPT BioRobotics (PRCT), suggesting limited near-term conviction while investors await greater clarity on demand, sales execution and the company’s outlook. PROCEPT BioRobotics Receives Average Hold Recommendation
• Negative Sentiment: Multiple firms announced or promoted a securities class action covering investors who purchased PRCT shares from February 28, 2024, through February 25, 2026. Investors have until September 22, 2026 to seek appointment as lead plaintiff. The legal notices themselves do not establish wrongdoing, but they add reputational, litigation and potential financial risks for the company. PROCEPT Investor Class Action Deadline
• Negative Sentiment: The allegations center on repeated underperformance in unit handpiece sales, a widening gap between handpiece shipments and procedures, and excess customer inventory reportedly built through late-quarter bulk discounts. Plaintiffs also allege that management attributed revenue volatility to temporary saline shortages while allegedly understating inventory-related problems. PROCEPT Securities Fraud Class Action Allegations

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.